Hodgkin Lymphoma, Version 2.2015

Abstract

Hodgkin lymphoma (HL) is an uncommon malignancy involving lymph nodes and the lymphatic system. Classical Hodgkin lymphoma (CHL) and nodular lymphocyte-predominant Hodgkin lymphoma are the 2 main types of HL. CHL accounts for most HL diagnosed in the Western countries. Chemotherapy or combined modality therapy, followed by restaging with PET/CT to assess treatment response using the Deauville criteria (5-point scale), is the standard initial treatment for patients with newly diagnosed CHL. Brentuximab vedotin, a CD30-directed antibody-drug conjugate, has produced encouraging results in the treatment of relapsed or refractory disease. The potential long-term effects of treatment remain an important consideration, and long-term follow-up is essential after completion of treatment.

Aggressive Natural Killer Cell Leukemia Secondary to Hodgkin Lymphoma: a Case Report and Review of the Literature

“…However, the toxicity of chemotherapy and radiotherapy should never be ignored. According to NCCN guidelines, developing secondary tumor is one of the most severe complications of HL during clinical follow up [12]. In HL patients, the risk of developing secondary lung and breast cancer are highly relevant to irradiation therapy (RT).…”

“…However, guidelines with regards of screening scope vary widely. According to NCCN guidelines, annual chest imaging (chest radiograph or CT) and breast screening (mammography or MRI) are suggested [12]. As secondary hematological malignancies were not uncommon following HL treatment, regular bone marrow examination may be also recommended to early define such abnormalities.…”

“…ABVD chemotherapy regimen followed by involved-field irradiation is the standard treatment for HL patients, effective in both early and advanced stages [12]. However, the toxicity of chemotherapy and radiotherapy should never be ignored.…”

“…In order to early detect secondary malignancies, clinical evaluations are recommended at 3-4 month intervals during the first and second year following completion of therapy, also at 6-month intervals in the third to fifth year and annually thereafter [12]. However, guidelines with regards of screening scope vary widely.…”

Excelente respuesta a tratamiento con ABVD en pacientes con linfoma de Hodgkin localizado

“…El esquema óptimo de tratamiento es aún controversial, pero ABVD (adriamicina, bleomicina, vinblastina y dacarbacina) es el esquema más recomendado 1,2 . El uso de RT es discutible, especialmente porque algunos estudios sugieren que pudiese aumentar el riesgo de mortalidad tardía tores de riesgo pueden ser tratados con esquemas libres de RT o con dosis bajas de RT (20 Gy) 4 .…”